MediciNova Announces Topline Results From MN-001-NATG-202, Its Phase 2 Clinical Trial Evaluating MN-001 (Tipelukast) For Treatment Of Hypertriglyceridemia And Nonalcoholic Fatty Liver Disease Associated With Type 2 Diabetes Mellitus; At Week 24, The...
